Entrada Therapeutics, Inc. (TRDA) Financials

TRDA Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 485.0 million 238.4 million
2023-06-30 494.0 million 287.1 million
2023-03-31 475.6 million 246.0 million
2022-12-31 252.1 million 39.5 million

TRDA Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -25.9 million 3.4 million
2023-06-30 -36.6 million 3.1 million
2023-03-31 201.7 million 2.8 million
2022-12-31 -28.0 million 2.9 million

TRDA Net Income

No data available :(

TRDA Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 353.6 million - 69.1 million
2023-06-30 376.8 million - 73.0 million
2023-03-31 227.6 million - 16.2 million
2022-12-31 45.2 million - 25.9 million

TRDA Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 34.8 million
2023-06-30 33.2 million
2023-03-31 32.4 million
2022-12-31 31.4 million

TRDA Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 1.4 million 22.2 million 7.5 million -
2023-06-30 1.5 million 26.3 million 8.2 million -
2023-03-31 1.7 million 23.1 million 7.9 million -
2022-12-31 708000 15.7 million 9.9 million -

TRDA Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 43.7 million 800000
2023-06-30 18.2 million 700000
2023-03-31 25.3 million 541000
2022-12-31 - 525000

TRDA

Price: $13.50

52 week price:
10.62
18.44

Earnings Per Share: -0.20 USD

P/E Ratio: -21.03

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 22900

Market Capitalization: 445.6 million

Links: